Diagnostics giant Labcorp is partnering with Getlabs to offer at-home sample collection for lab tests.
With the service, dubbed Getlabs for Labcorp, users can schedule an appointment online for an at-home blood draw. The phlebotomist can collect other samples like saliva, stool, urine, and breath, and also measure vital signs. The collection will cost a convenience fee starting at $25.
Miami, Fla.-based Getlabs, which also delivers specimens for Quest Diagnostics, scored $20 million in Series A financing earlier this year.
WHY IT MATTERS
Labcorp is pitching the partnership as a way to improve access to lab testing, including for people who can’t easily find transportation, those with disabilities, and people who are immunocompromised.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“We want to make it easy for people to manage their health and this collaboration with Getlabs significantly expands Labcorp’s home testing options to include our full range of tests,” Amy Summy, executive vice president, and chief marketing officer at Labcorp, said in a statement.
“The blend of easy scheduling online, our full set of tests, and in-person testing make it simple for individuals who want the convenience of the at-home collection but are uncomfortable drawing their own blood or require diagnostic tests beyond those offered through Labcorp’s at-home kits.”
THE LARGER TREND
Labcorp has been expanding its reach in digital health and at-home care. In February, the company launched a new digital diagnostics platform, called Labcorp OnDemand, where consumers could order tests and possibly collect samples at home. That offering replaced Pixel with Labcorp, which launched with a more limited line of tests.
Last year, Labcorp acquired Ovia Health, a reproductive and family care platform.
However, there are several competitors touting at-home testing. Everly Health, the parent company of diagnostic startup EverlyWell, also acquired its own reproductive health-focused company, Natalist, in 2021.
Rapid diagnostics startup Cue Health went public last year. The company currently offers an at-home molecular COVID-19 test but is working on expanding its diagnostic tools.
Another player in the space is LetsGetChecked, which wrapped up a $150 million Series D funding round in June.
Source: Mobihealthnews
